Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $984.62 | 13 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $802.48 | 8 | $0 (2020) |
| ABBVIE INC. | $154.16 | 3 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $16.00 | 1 | $0 (2017) |
| Theravance Biopharma, Inc. | $11.98 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $154.16 | 3 | ABBVIE INC. ($154.16) |
| 2020 | $129.59 | 1 | Allergan, Inc. ($129.59) |
| 2019 | $391.87 | 3 | Allergan Inc. ($391.87) |
| 2018 | $148.15 | 3 | Allergan Inc. ($136.17) |
| 2017 | $160.85 | 3 | Allergan Inc. ($144.85) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/20/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $109.62 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/07/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $33.15 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/03/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/16/2020 | Allergan, Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $129.59 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/20/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/11/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $116.87 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/26/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/21/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $11.98 | General |
| Category: Infectious Disease | ||||||
| 04/23/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/28/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $123.80 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/17/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $123.22 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/07/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/27/2017 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA, SIVEXTRO | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 146 | 325 | $146,870 | $36,960 |
| 2022 | 3 | 76 | 206 | $73,450 | $28,709 |
| 2021 | 3 | 95 | 198 | $62,970 | $25,970 |
| 2020 | 3 | 129 | 293 | $92,720 | $38,313 |
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 14 | 80 | $53,551 | $14,851 | 27.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 132 | $42,504 | $9,537 | 22.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 59 | 62 | $32,155 | $7,239 | 22.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 51 | $18,660 | $5,333 | 28.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 19 | 97 | $38,800 | $18,026 | 46.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 28 | 70 | $21,000 | $6,158 | 29.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 29 | 39 | $13,650 | $4,526 | 33.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 17 | 66 | $31,500 | $12,558 | 39.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 77 | $17,220 | $6,912 | 40.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 47 | 55 | $14,250 | $6,500 | 45.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 21 | 101 | $55,550 | $19,329 | 34.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 54 | 134 | $24,120 | $12,162 | 50.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 54 | 58 | $13,050 | $6,822 | 52.3% |
About Dr. Avisheh Forouzesh, MD
Dr. Avisheh Forouzesh, MD is a Infectious Disease healthcare provider based in Hoboken, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346273778.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Avisheh Forouzesh, MD has received a total of $984.62 in payments from pharmaceutical and medical device companies, with $154.16 received in 2022. These payments were reported across 13 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($984.62).
As a Medicare-enrolled provider, Forouzesh has provided services to 446 Medicare beneficiaries, totaling 1,022 services with total Medicare billing of $129,952. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Hoboken, NJ
- Active Since 07/09/2006
- Last Updated 11/13/2014
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1346273778
Products in Payments
- TEFLARO (Drug) $369.68
- DALVANCE (Drug) $353.54
- AVYCAZ (Drug) $233.42
- CUBICIN RF (Drug) $16.00
- VIBATIV (Drug) $11.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.